Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.53 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | SCD | O00767 | 2/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | SENP1 | Q9P0U3 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3369612 | 0.83 | KMT2A (0.56) | CHRM4KMT2AMAPK1ALDH1A1LMNA | |
| SCHEMBL3049318 | 0.83 | KMT2A (0.66) | KMT2AMAPK1RAB9AL3MBTL1ALDH1A1 | |
| SCHEMBL3369239 | 0.80 | CHRM4 (0.56) | CHRM4MAPK1RAB9ASCDEPHX2 | |
| SCHEMBL15421497 | 0.76 | NAMPT (0.62) | KMT2ARAB9AALDH1A1LMNAHPGD | |
| SCHEMBL20804355 | 0.75 | HPGD (0.57) | KMT2AMAPK1RAB9AALDH1A1HPGD | |
| SCHEMBL10194841 | 0.75 | MMP13 (0.61) | KMT2AALDH1A1LMNA | |
| SCHEMBL13082534 | 0.75 | CHRM4 (0.62) | CHRM4KMT2ARAB9AADORA2AADORA2B | |
| SCHEMBL2009061 | 0.75 | SLC6A9 (0.63) | KMT2ARAB9AL3MBTL1 | |
| SCHEMBL3109722 | 0.75 | SRC (0.61) | MAPK1RAB9AEPHX2ALDH1A1 | |
| SCHEMBL29699631 | 0.75 | SRC (0.61) | MAPK1RAB9AEPHX2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140024583-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2014-01-23 | — | — | US | disclosed |
| US-8501746-B2 | Organic compounds | XENON PHARMACEUTICALS INC. (CA) | 2013-08-06 | — | — | US | disclosed |
| WO-2007143597-A9 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-11-11 | — | — | WO | disclosed |
| EP-2029572-B1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-11-03 | — | — | EP | disclosed |
| US-20090156615-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-06-18 | — | — | US | disclosed |
| EP-2029572-A2 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007143597-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2007-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156615-A1 | ORGANIC COMPOUNDS | SCD, SCD5, FADS2 | CHRM4 3011/4885KMT2A 2098/4885MAPK1 4752/4885 |
| US-20140024583-A1 | ORGANIC COMPOUNDS | SCD, SCD5, FADS2 | CHRM4 3011/4885KMT2A 2098/4885MAPK1 4752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.